MERISTEM Therapeutics &Amp; SBH Sciences Announce Agreement for Joint Development of Animal-Free Recombinant Proteins
Posted on: Thursday, 15 November 2007, 12:00 CST
MERISTEM Therapeutics and SBH Sciences have entered an agreement to co-develop recombinant proteins produced in genetically engineered tobacco for research and development and diagnostic applications. The first proteins selected for development are human proteins from the growth factor and hormone families. Through the combined expertise of MERISTEM and SBH the companies will strive to provide a large variety of human proteins to Research and Development organizations. Meristem's experience and know-how in plant-based stable expression of proteins combined with SBH's customized purification technology will ensure speed up of production and superior quality of proteins. Proteins expressed in Meristem's system are free of pathogens transmissible to humans.
About MERISTEM Therapeutics
MERISTEM Therapeutics ("MERISTEM") of Clermont-Ferrand, France is a private, venture-capital backed Biotechnology Company that has developed advanced manufacturing capabilities for the production of recombinant proteins in plants. Meristem's transgenic plant technology competes with established methods of manufacturing biopharmaceuticals and is considered a cost-effective alternative for proteins difficult to express in other systems.
Expression technologies using non-food plants grown in a contained environment is the latest advancement for MERISTEM. This technology is being utilized for applications in both animal and human health. Key advantages are the safety of a confined and controlled environment without sacrificing the capability to scale-up production quickly and cost-effectively.
About SBH Sciences
SBH Sciences (Natick, MA.) provides cell culture based services to the Biotechnology and Pharmaceutical industry and academic researchers. In its tenth year of operation, SBH Sciences is making significant advances in proprietary cell culture technology, specifically in mammalian and insect cell culture, optimizing in-vitro diagnostic methods, as well as customizing the production and purification of proteins.
SBH Sciences excels in the development and validation of cell-based bioassays for biologically active cytokines and currently has the most comprehensive assay library worldwide. Assays consist of over 200 different cytokines, cytokine receptors and anti-cytokines, with assay endpoints including proliferation, neutralization, cytotoxicity, complement dependent cytotoxicity, agonistic and antagonistic activities. They specialize in cytokine and protein profiling as well as immunological based assays.
Contact: Kathleen Marker Manager Business Development MERISTEM® Therapeutics Tel 33 473 98 68 45 Fax 33 473 98 68 19 Email: Email Contact
SOURCE: MERISTEM Therapeutics
Source: MARKET WIRE
Related Articles
- Drug Development Program Started Based on CAP(R) Human Cell Line
- Musculoskeletal Transplant Foundation Announces Major Development Milestone in Stem Cell Allograft Product
- Xenomis LLC Signs Licensing Agreement With Harvard Medical School For Technology to Assist in the Development of Nutraceutical Products Based Upon Proprietary Stressed Plant Science
- Invitrogen and Biocon Announce Exclusive Agreement to Supply New Source of Insulin to Global Cell Culture Market
- Pioneering Vaccine and Cell Culture Expert Joins HepaLife to Expedite Development of Avian Flu Vaccine
- Geron Announces Issuance of U.S. Patent for Production of Insulin Secreting Cells From Human Embryonic Stem Cells
- Bruker Daltonics and German Collection of Microorganisms and Cell Cultures
- Geron Announces Improved Production Method for Human Embryonic Stem Cell-Derived Islet Cells
- Chiron Initiates U.S. Phase I/II Study of Influenza Cell Culture Vaccine
- Insect Cell Culture in Research: Indian Scenario
 |
 |
User Comments (0)
RSS Feeds